Figure 6
Loss of CD4+IL-21+ T cells is associated with preferential depletion of Th17 cells and increased T-cell proliferation in chronically SIV-infected RMs. (A) Positive correlation between the absolute level of CD4+IL-21+ T cells (expressed as number per microliter) and the percentages of Th17 cells in blood. (B) Positive correlation between the absolute levels of intestinal CD4+IL-21+ T cells in rectal mucosa (expressed as percentage of total CD3+) and the percentages of Th17 cells in rectal mucosa. In blood, the percentage of CD4+IL-21+ T cells correlated directly with the percentage of CD4+ T cells (C) and inversely with the percentage of proliferating (Ki-67+) CD8+ T cells (D). At the level of intestinal mucosa, the percentage of CD4+IL-21+ T cells correlated negatively with the percentage of intestinal CD4+Ki-67+ (E) and CD8+Ki-67+ (F) T cells. (G) Three chronically SIV-infected RMs (day 380 after infection) were treated in vivo with 5 weekly doses of IL-21. Percentages of CD4+IL-17+ (left panel) and CD4+IL-17+IL-21+ (right panel) T cells were compared before and after IL-21 treatment. Numbers close to the symbols indicate fold increase compared to baseline.

Loss of CD4+IL-21+ T cells is associated with preferential depletion of Th17 cells and increased T-cell proliferation in chronically SIV-infected RMs. (A) Positive correlation between the absolute level of CD4+IL-21+ T cells (expressed as number per microliter) and the percentages of Th17 cells in blood. (B) Positive correlation between the absolute levels of intestinal CD4+IL-21+ T cells in rectal mucosa (expressed as percentage of total CD3+) and the percentages of Th17 cells in rectal mucosa. In blood, the percentage of CD4+IL-21+ T cells correlated directly with the percentage of CD4+ T cells (C) and inversely with the percentage of proliferating (Ki-67+) CD8+ T cells (D). At the level of intestinal mucosa, the percentage of CD4+IL-21+ T cells correlated negatively with the percentage of intestinal CD4+Ki-67+ (E) and CD8+Ki-67+ (F) T cells. (G) Three chronically SIV-infected RMs (day 380 after infection) were treated in vivo with 5 weekly doses of IL-21. Percentages of CD4+IL-17+ (left panel) and CD4+IL-17+IL-21+ (right panel) T cells were compared before and after IL-21 treatment. Numbers close to the symbols indicate fold increase compared to baseline.

Close Modal

or Create an Account

Close Modal
Close Modal